

**Cancer Prevention and Research Institute of Texas**  
**Quarterly Financial Report**  
As of November 30, 2023

**Indirect Administration (B.1.1.)**

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
1001 Salaries and Wages	\$ 1,847,425	\$ 1,862,286		\$ 480,872	1,381,415	26%	\$ 480,872	\$ 1,381,415
1002 Other Personnel Costs	38,785	38,785		6,158	32,628	16%	6,158	32,628
2001 Professional Fees and Services	1,808,662	2,118,039		552,395	1,565,644	26%	552,395	1,565,644
2003 Consumable Supplies	24,000	24,000		839	23,161	3%	839	23,161
2004 Utilities	58,600	58,600		40,567	18,033	69%	40,567	18,033
2005 Travel	45,000	45,000		24,132	20,868	54%	24,132	20,868
2006 Rent-Building	11,000	11,000		2,334	8,666	0%	2,334	8,666
2007 Rent-Machine and Other	32,172	32,172		7,460	24,712	23%	7,460	24,712
2009 Other Operating Expenses	1,045,249	1,645,249		557,250	1,087,999	34%	557,250	1,087,999
<b>Subtotal - Indirect Administration (B.1.1.)</b>	<b>\$ 4,910,893</b>	<b>\$ 5,835,132</b>	<b>1.96%</b>	<b>\$ 1,672,006</b>	<b>\$ 4,163,125</b>	<b>29%</b>	<b>\$ 1,672,006</b>	<b>\$ 4,163,125</b>

**Grant Review and Award Operations (A.1.3.)**

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
1001 Salaries and Wages	\$ 3,505,873	3,332,230		\$ 1,049,153	\$ 2,283,077	31%	\$ 1,049,153	\$ 2,283,077
1002 Other Personnel Costs	45,000	45,000		11,609	33,391	0%	11,609	33,391
2001 Professional Fees and Services	12,419,373	12,520,777		10,971,478	1,549,299	88%	10,971,478	1,549,299
2003 Consumable Supplies	-	-		-	-	0%	-	-
2004 Utilities	12,000	12,000		-	12,000	0%	-	12,000
2005 Travel	45,000	45,000		7,763	37,237	17%	7,763	37,237
2009 Other Operating Expenses	71,649	342,148		6,458	335,691	2%	6,458	335,691
<b>Subtotal - Grant Operations (A.1.3.)</b>	<b>\$ 16,098,895</b>	<b>\$ 16,297,155</b>	<b>5.47%</b>	<b>\$ 12,046,460</b>	<b>\$ 4,250,695</b>	<b>74%</b>	<b>\$ 12,046,460</b>	<b>\$ 4,250,695</b>

**Grants**

	2024 Appropriated	2024 Budgeted	% of Total Budget	Actual Expenditures & Grant Encumbrances (FYTD)	Remaining Budget	Percent Expended	Estimated Expenditures (YTD)	Lapse/Overspent
4000 Grants - Prevention (A.1.2)	\$ 27,671,780	\$ 27,544,573		\$ -	\$ 27,544,573	0%	\$ -	\$ 27,544,573
4000 Grants - Research (A.1.1.)	248,251,400	\$ 248,251,400		63,196,634	\$ 185,054,766	25%	63,196,634	185,054,766
<b>Subtotal - Grants</b>	<b>\$ 275,923,180</b>	<b>\$ 275,795,973</b>	<b>92.57%</b>	<b>\$ 63,196,634</b>	<b>\$ 212,599,339</b>	<b>23%</b>	<b>\$ 63,196,634</b>	<b>\$ 212,599,339</b>
<b>Grand Totals</b>	<b>\$ 296,932,968</b>	<b>\$ 297,928,260</b>	<b>100.00%</b>	<b>\$ 76,915,101</b>	<b>\$ 221,013,159</b>	<b>26%</b>	<b>\$ 76,915,101</b>	<b>\$ 221,013,159</b>

**Cancer Prevention and Research Institute of Texas  
Cancer Prevention and Research Institute Fund Account - 5136  
As of November 30, 2023**

	<b>11/01/2023- 11/30/2023</b>	<b>AY 23 Year to Date as of 11/30/2023</b>
<b>Beginning Balance : 9/01/2023</b>		<b>\$ 600,506</b>
<b>Increases:</b>		
(1)	\$ -	\$ -
(2)	-	
<b>Total Increases</b>	<b>\$ -</b>	<b>\$ 600,506.00</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	\$ -
	\$ -	\$ -
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 11/30/2023</b>		<b>\$ 600,506.00</b>

Note: (1) The Institute received a settlement from the Texas Cancer Coalition (TCC). This amount represents the final distribution and transfer of all funds (\$303,877) from the TCC which ceased operations in May 2013. These funds are in the State Treasury but are not appropriated to CPRIT. The beginning balance reflects the transfer of all TCC funds.

**Cancer Prevention and Research Institute of Texas  
License Plate Trust Fund Account - 0802  
As of November 30, 2023**

	<b>11/01/2023- 11/30/2023</b>	<b>AY 23 Year to Date as of 11/30/2023</b>
<b>Beginning Balance : 9/01/2023</b>		<b>\$ 101,766.48</b>
<b>Increases:</b>		
(1) License Plate Revenue Received	\$ 339.16	\$ 1,325.48
Interest	\$ 168.81	\$ 514.65
<b>Total Increases</b>	<b>\$ 507.97</b>	<b>\$ 103,606.61</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	-	-
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 11/30/2023</b>		<b>\$ 103,606.61</b>

Note:

Balance forward from 2023 License Plate \$101,766.48

**Cancer Prevention and Research Institute of Texas**

**Appropriated Receipts - 666**

**As of November 30, 2023**

	<u>11/01/2023-</u> <u>11/30/2023</u>	<u>AY 23 Year to Date as of</u> <u>11/30/2023</u>
<b><u>Beginning Balance : 9/01/2023</u></b>		<b>\$ 243,044.65</b>
<b>Increases:</b>		
(1) Product Development Application Fees Received	\$ -	\$ -
(2) Conference Registration Fees	\$ -	\$ 80,940.00
(3) Conference Registration Fees-Credit Card	\$ -	\$ 1,761.70
<b>Total Increases</b>	<b><u>\$ -</u></b>	<b><u>\$ 82,701.70</u></b>
<b>Reductions:</b>		
Conference Expenditures - Appropriated	\$ -	\$ -
Credit Card Fees Expended	\$ (1,124.54)	\$ (1,124.54)
Refund-Application Fees	\$ -	\$ -
Legal Services Expenses (Application Fees)	\$ -	\$ -
<b>Total Reductions</b>	<b><u>\$ (1,124.54)</u></b>	<b><u>\$ (1,124.54)</u></b>
<b><u>Ending Balance: 11/30/2023</u></b>		<b><u><u>\$ 324,621.81</u></u></b>

Forward balance for FY 2022 is \$55,246.90  
 Application Fees  
 Conference Fee for FY 2023 is \$187,797.75

**Cancer Prevention and Research Institute of Texas**  
**Interest & Sinking Fund Account - 5168**  
**As of November 30, 2023**

	<b>11/01/2023- 11/30/2023</b>	<b>AY 23 Year to Date as of 11/30/2023</b>
<b>Beginning Balance : 9/01/2023</b>		<b>\$ 6,390,606.01</b>
<b>Increases:</b>		
(1) Revenue Sharing / Royalties	\$ 104,746.30	\$ 138,189.00
	\$ -	\$ -
<b>Total Increases</b>	<b>\$ 104,746.30</b>	<b>\$ 6,528,795.01</b>
<b>Reductions:</b>		
Expenditures - Appropriated	\$ -	\$ -
	\$ -	\$ -
	\$ -	\$ -
<b>Total Reductions</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Ending Balance: 11/30/2023</b>		<b>\$ 6,528,795.01</b>

Balance forward from FY 2023 is \$6,390,606.01